Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Cadence Bank stock price: CADE frozen after Huntington takeover, focus shifts to HBAN

Cadence Bank stock price: CADE frozen after Huntington takeover, focus shifts to HBAN

Cadence Bank shares remain halted after closing at $42.11 on Jan. 30, as each share converts to 2.475 shares of Huntington Bancshares under a finalized merger. Huntington traded at $19.02 premarket Friday. Huntington will keep all Cadence branches open and aims to finish customer account conversions by mid-2026. Investors await Huntington’s February 10 appearance at a UBS conference.
6 February 2026
··
Ondas (ONDS) stock rebounds in premarket after J Capital report rattles investors

Ondas (ONDS) stock rebounds in premarket after J Capital report rattles investors

Ondas Inc shares rose 4.7% to $8.88 in premarket trading Friday after plunging over 25% since Tuesday. The rebound follows a bearish J Capital report criticizing Ondas’ reliance on share offerings and questioning its growth prospects. CEO Eric Brock sold $4.6 million in shares on Dec. 31. Ondas recently announced a new Asia-Pacific defense contract and its planned acquisition of UK-based Rotron Aero.
6 February 2026
Palantir stock drops again before the bell as AI shakeout hits software — what investors watch next

Palantir stock drops again before the bell as AI shakeout hits software — what investors watch next

Palantir shares fell 6.8% in premarket trading Friday to $130.01, extending a sharp slide after Alphabet’s $185 billion capex plan rattled AI software stocks. The drop followed a 6.8% loss Thursday and nearly 12% Wednesday, despite Palantir’s new partnership with Cognizant and Q4 revenue of $1.407 billion. The S&P 500 software index has dropped seven days straight. Investors await key U.S. data and sector earnings next week.
6 February 2026
·
Kenvue stock price today: KVUE ticks up premarket as Feb. 17 results near, earnings call scrapped

Kenvue stock price today: KVUE ticks up premarket as Feb. 17 results near, earnings call scrapped

Kenvue shares rose 0.2% premarket Friday after the company set Feb. 17 for its earnings release and said it will not hold a quarterly call due to its pending deal with Kimberly-Clark. Each Kenvue share will convert into 0.14625 Kimberly-Clark shares plus $3.50 cash if the merger closes, leaving Kenvue stock about 70 cents below the implied value. Investors remain focused on deal timing and ongoing product litigation.
6 February 2026
···
Atlassian stock price slips in premarket after earnings; TEAM eyes cloud-growth slowdown and fresh target cuts

Atlassian stock price slips in premarket after earnings; TEAM eyes cloud-growth slowdown and fresh target cuts

Atlassian shares fell 6.3% to $98.41 in premarket trading after reporting fiscal Q2 revenue of $1.586 billion and a GAAP net loss of $42.6 million. Several brokers cut price targets following the results. Cloud revenue rose 26% to $1.067 billion, but guidance points to slower growth ahead. The stock is down over 66% in the past year.
6 February 2026
···
Nvidia stock bounces in premarket as Amazon’s $200B AI spend stirs the trade; China chip licences in focus

Nvidia stock bounces in premarket as Amazon’s $200B AI spend stirs the trade; China chip licences in focus

Nvidia shares rose 2.7% in premarket trading Friday after the Nasdaq hit a two-month low. Amazon shares dropped 8% premarket following news its 2026 capital expenditures could reach $200 billion. Nvidia’s supply chain pushed back on AI bubble fears, while export policy talks with ByteDance remain unresolved. Investors await Nvidia’s Feb. 25 earnings and key U.S. economic data next week.
6 February 2026
·····
Doximity (DOCS) stock slips premarket after soft outlook, CFO medical leave, new $500 million buyback

Doximity (DOCS) stock slips premarket after soft outlook, CFO medical leave, new $500 million buyback

Doximity shares fell 5.4% to $33.32 premarket after the company forecast slower growth and said CFO Anna Bryson is on medical leave. Chief Accounting Officer Siddharth Sitaram was named interim finance head. The board approved a $500 million share buyback. Fiscal Q3 revenue rose 10% to $185.1 million, but Q4 guidance was below expectations.
6 February 2026
··
Coloplast A/S stock sinks nearly 8% as Medicare reimbursement change hits Kerecis outlook

Coloplast A/S stock sinks nearly 8% as Medicare reimbursement change hits Kerecis outlook

Coloplast A/S shares fell 7.82% to 495.35 crowns in Copenhagen after the company slashed its Kerecis growth forecast to 10% due to new U.S. Medicare reimbursement rules. Group revenue for the quarter was flat at 7,043 million crowns, with EBIT before special items down 3% to 1,850 million. Coloplast will phase out Kerecis Shield in Medicare outpatient care and shift focus to its MariGen range.
6 February 2026
·
Fortinet stock rises in premarket after earnings beat and upbeat 2026 outlook

Fortinet stock rises in premarket after earnings beat and upbeat 2026 outlook

Fortinet shares rose 2.8% to $81.11 premarket after quarterly earnings and revenue beat forecasts, with billings climbing to $2.37 billion. Adjusted earnings reached 81 cents per share on $1.91 billion revenue. The company projected first-quarter earnings below some estimates and approved a $1 billion increase to its share buyback program. Service revenue growth lagged, raising questions about renewal momentum.
6 February 2026
·
Kongsberg Gruppen ASA stock price jumps 14% as Q4 backlog hits record and €140m weapons order lands

Kongsberg Gruppen ASA stock price jumps 14% as Q4 backlog hits record and €140m weapons order lands

Kongsberg shares jumped 14% to 367.15 crowns after reporting record Q4 results and a €140 million weapons contract. The company set a regular 2.20 crowns and special 3.50 crowns dividend, pending April 13 approval. Order backlog reached 157.4 billion crowns. Kongsberg confirmed plans to spin off its maritime unit with a separate listing targeted for April 23.
6 February 2026
··
Nebius stock snaps higher in premarket after two-day slide as NBIS earnings near

Nebius stock snaps higher in premarket after two-day slide as NBIS earnings near

Nebius Group N.V. shares rose 4.8% to $77.41 in premarket trading Friday, rebounding after an 18% two-day drop amid a broader tech selloff. The Amsterdam-based AI cloud firm will report fourth-quarter and full-year 2025 results on Feb. 12. Investors are focused on Nebius’s spending plans and revenue outlook as scrutiny of capital expenditures in the sector intensifies.
6 February 2026
··
Lithium price slips again in China, dragging Albemarle and SQM shares lower before Wall Street opens

Lithium price slips again in China, dragging Albemarle and SQM shares lower before Wall Street opens

China’s battery-grade lithium carbonate price fell about 4% to 134,500 yuan per tonne, pressuring lithium stocks in U.S. premarket trading. Albemarle dropped 7.2%, SQM slipped 4%, and Lithium Americas lost 8.6%. Shanghai Metals Market said downstream stockpiling ahead of Lunar New Year is nearly complete. LME lithium hydroxide CIF slid 3.3% to $17,600 per tonne.
6 February 2026
··
1 … 9 10 11 12 13 … 535

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop